Monitor next 10-Q for updates on pipeline progress or cash position, as current insider sales are routine and not materially bearish. No immediate catalyst implied, but continued selling ahead of earnings or dilutive financing could shift sentiment.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 15 $89.00entry
- T+1 · 7mo ago −3.21%α −3.47% · $86.14
- T+5 · 7mo ago −0.26%α −1.90% · $88.77
- T+20 · 6mo ago −6.12%α −12.17% · $83.55
- T+60 · 4mo ago +34.10%α +25.96% · $119.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Kymera Therapeutics sold a combined $315K in shares within a 7-day window, including COO Chadwick Jeremy G and Director Bruce Booth. The sales represent a modest 0.004% of the company's $7.1B market cap and align with recent open-market dispositions, suggesting routine portfolio management rather than a strong negative signal.
Key Financial Metrics
Key Facts
- COO Chadwick Jeremy G sold 1,300 shares for $117K on 2026-04-15 and exercised/withheld shares on 2026-04-22 (non-cash transactions totaling $3,017)
- Director Bruce Booth sold 2,200 shares for $198K on 2026-04-15
- Total open-market sales in cluster: $315K
- Cluster value represents 0.004% of $7.1B market cap
- Recent 30-day insider activity includes $342K in total sales, indicating ongoing selling pressure
Financial Impact
$315,000 in open-market sales (0.004% of market cap)
Risk Factors
- Prolonged insider selling could erode investor confidence
- Biotech stocks are sensitive to cash runway and clinical trial updates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KYMR-1777062653014 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers